Buprenorphine in the Treatment of Opiate Dependence: Its Pharmacology and Social Context of Use in the U.S.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Psychoactive Drugs

• Publication date

  2004-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1080/02791072.2004.10400047PMID 15279124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats

  2004cited by this paper
• Clinical efficacy of buprenorphine: comparisons to methadone and placebo.

  2003cited by this paper
• Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.

  2003cited by this paper
• Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

  2003cited by this paper
• Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

  2003cited by this paper
• From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.

  2003cited by this paper
• Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

  2003cited by this paper
• Enzyme immunoassay validation for the detection of buprenorphine in urine.

  2003cited by this paper
• Buprenorphine and midazolam act in combination to depress respiration in rats.

  2002cited by this paper
• Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.

  2002cited by this paper
• Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat

  2002cited by this paper
• A new series of 13 buprenorphine-related deaths.

  2002cited by this paper
• Medications in the treatment of addiction: workplace issues.

  2002cited by this paper
• Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine.

  2001cited by this paper
• Buprenorphine Treatment of Heroin Dependence (Detoxification and Maintenance) in a Private Practice Setting

  2001cited by this paper
• Office-based treatment for opioid dependence: reaching new patient populations.

  2001cited by this paper
• Deaths involving buprenorphine: a compendium of French cases.

  2001cited by this paper
• Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

  2001cited by this paper
• Injecting misuse of buprenorphine among French drug users.

  2001cited by this paper
• Lack of interaction of buprenorphine with flunitrazepam metabolism.

  2000cited by this paper
• A longitudinal study of male buprenorphine addicts attending an addiction clinic in India.

  2000cited by this paper
• Buprenorphine and Naloxone for Heroin Dependence

  2000cited by this paper
• Buprenorphine-Induced Changes in Mu-Opioid Receptor Availability in Male Heroin-Dependent Volunteers: A Preliminary Study

  2000cited by this paper
• Epidemiology of hepatitis C virus infection in Nepal.

  1998cited by this paper
• Reentry using naltrexone: one anesthesia department's experience.

  1998cited by this paper
• Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.

  1998cited by this paper
• Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.

  1998cited by this paper
• Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.

  1998cited by this paper
• Bioavailability of Sublingual Buprenorphine

  1997cited by this paper
• [Misuse of buprenorphine-benzodiazepines combination: 6 deaths].

  1997cited by this paper
• Naltrexone pharmacotherapy for opioid dependent federal probationers.

  1997cited by this paper
• Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.

  1997cited by this paper
• International Union of Pharmacology. XII. Classification of opioid receptors.

  1996cited by this paper
• Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.

  1996cited by this paper
• Drug abuse in Nepal: a rapid assessment study.

  1996cited by this paper
• A pilot study of primary-care-based buprenorphine maintenance for heroin dependence.

  1996cited by this paper
• Pharmacokinetics of Opioids in Renal Dysfunction

  1996cited by this paper
• Acute administration of buprenorphine in humans: partial agonist and blockade effects.

  1995cited by this paper
• Buprenorphine: combatting drug abuse with a unique opioid

  1995cited by this paper
• Drug injectors in Glasgow: a community at risk? A report from a multidisciplinary group. The Possilpark Group.

  1993cited by this paper
• Development of a radioimmunoassay for the determination of buprenorphine in biological samples.

  1993cited by this paper
• Cases of buprenorphine abuse in India

  1992cited by this paper
• [Subgroups of drug abuse patients who consume buprenorphine].

  1991cited by this paper
• Buprenorphine abuse: report from India.

  1990cited by this paper
• Clinical toxicology of drugs used in the treatment of opiate dependency.

  1990cited by this paper
• Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic.

  1989cited by this paper
• Buprenorphine and temazepam abuse by drug takers in Glasgow--an increase.

  1989cited by this paper
• Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure.

  1989cited by this paper
• Kappa antagonist properties of buprenorphine in the shock titration procedure.

  1988cited by this paper
• Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice

  1988cited by this paper
• Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice.

  1988cited by this paper
• Buprenorphine has potent kappa opioid receptor antagonist activity.

  1987cited by this paper
• Abuse of buprenorphine.

  1986cited by this paper
• Abuse of buprenorphine.

  1985cited by this paper
• Naltrexone in addicted business executives and physicians.

  1984cited by this paper
• Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience.

  1984cited by this paper
• Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.

  1982cited by this paper
• Biliary excretion, metabolism and enterohepatic circulation of buprenorphine.

  1981cited by this paper
• Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

  1978cited by this paper
• The American disease : origins of narcotic control

  1974cited by this paper
• Problems of Drug Dependence

  1969cited by this paper

• Understanding Opioid Use Disorder: the Paradoxical Co-occurrence of Reward and Aversion during Intoxication

  2025cites this paper
• Harm reduction interventions for AYA who use opioids: A scoping review.

  2025cites this paper
• Bupenorphine in Wisconsin Drivers: Concerns for Impairment?

  2019cites this paper
• Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers

  2018cites this paper
• Buprenorphine oral lyophilisate (Espranor®) in the substitution treatment of opioid dependence: a profile of its use

  2017cites this paper
• Buprenorphine oral lyophilisate (Espranor®) in the substitution treatment of opioid dependence: a profile of its use

  2017cites this paper
• Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program

  2017cites this paper
• The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales

  2015cites this paper
• Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective

  2015cites this paper
• Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence

  2014cites this paper
• Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA

  2013cites this paper
• Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA

  2013cites this paper
• Buprenorphine/Naloxone

  2012cites this paper
• Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

  2011cites this paper
• Brief vs. Extended Buprenorphine Detoxification in a Community Treatment Program: Engagement and Short-Term Outcomes

  2009cites this paper
• Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

  2009cites this paper
• Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.

  2008cites this paper
• Neurochemical Adaptations and Cocaine Dependence

  2007cites this paper
• Poor Man's Smack: A Qualitative Study of Buprenorphine Injecting in Melbourne, Australia

  2007cites this paper
• Buprenorphine Treatment

  2007cites this paper
• Factors Determining How Early Adopter Physicians Use Buprenorphine in Treatment

  2007cites this paper
• Partial agonism of dopamine, serotonin and opiate receptors for psychiatry

  2006cites this paper
• Recent development and potential use of µ‐ and κ‐opioid receptor ligands in positron emission tomography studies

  2006cites this paper
• Plazebokontrollierte Blindstudie zur postoperativen Schmerztherapie mit Carprofen und Buprenorphin bei Hunden mit Frakturen

  2006cites this paper
• Differential activation of G‐proteins by μ‐opioid receptor agonists

  2006cites this paper
• Anti-nociceptive efficacy of carprofen, levomethadone and buprenorphine for pain relief in cats following major orthopaedic surgery.

  2005cites this paper
• Can Drug Design Inhibit Abuse?

  2005cites this paper